Format

Send to

Choose Destination
Clin Vaccine Immunol. 2012 Jul;19(7):991-8. doi: 10.1128/CVI.00031-12. Epub 2012 May 23.

Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Author information

1
Novartis Vaccines and Diagnostics S.r.l., Siena, Italy. yasushi.uematsu@novartis.com

Abstract

Antivector immunity has been recognized as a potential caveat of using virus-based vaccines. In the present study, an alphavirus-based replicon particle vaccine platform, which has demonstrated robust immunogenicity in animal models, was tested for effects of antivector immunity on immunogenicity against hemagglutinin of influenza virus as a target antigen and efficacy for protection against lethal challenge with the virus. Chimeric alphavirus-based replicon particles, comprising Venezuelan equine encephalitis virus nonstructural and Sindbis virus structural components, induced efficient protective antibody responses, which were not adversely influenced after multiple immunizations with the same vector expressing various antigens.

PMID:
22623651
PMCID:
PMC3393363
DOI:
10.1128/CVI.00031-12
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center